Analysis of U.S. Patent 8,791,140: Scope, Claims, and Landscape
U.S. Patent 8,791,140, titled "Method of treating a condition with a compound, the compound is 1-(2,6-difluoro-3-methoxyphenyl)-2-[4-(4-fluoro-2-methyl-1H-imidazol-2-yl)phenyl]ethanone," was granted to Bristol-Myers Squibb Company on August 26, 2014. The patent covers a method of treating a specific condition using a chemical compound. This analysis details the patent's scope, examines its core claims, and assesses its position within the broader drug patent landscape.
What is the Subject Matter of U.S. Patent 8,791,140?
The patent's subject matter is a method of treating a condition with a specific chemical compound. The compound is identified by its chemical name: 1-(2,6-difluoro-3-methoxyphenyl)-2-[4-(4-fluoro-2-methyl-1H-imidazol-2-yl)phenyl]ethanone. This compound is also known by its investigational drug name, BMS-986165, which is developed for treating autoimmune diseases.
The "condition" to be treated is broadly defined within the patent, but its practical application focuses on inflammatory and autoimmune conditions. The patent claims a method that involves administering a therapeutically effective amount of the specified compound to a subject.
What are the Key Claims of U.S. Patent 8,791,140?
U.S. Patent 8,791,140 has multiple claims, but the core of the patent protection lies in its method of use claims.
Claim 1: Method of Treatment
This is the central claim of the patent. It defines a method for treating a condition. The method involves administering a therapeutically effective amount of the compound 1-(2,6-difluoro-3-methoxyphenyl)-2-[4-(4-fluoro-2-methyl-1H-imidazol-2-yl)phenyl]ethanone to a patient. The patent specifies that the condition is one that can be treated by modulating the activity of a Janus kinase (JAK) enzyme. Specifically, it targets the JAK1 enzyme.
Claim 2: Specific Target Enzyme
This claim refines Claim 1 by specifying the targeted enzyme. The method is for treating a condition by inhibiting the activity of the JAK1 enzyme. This highlights the pharmacological mechanism of action the patent seeks to protect.
Claim 3: Further Specificity on Condition
This claim provides a more detailed description of the condition. It refers to a condition associated with aberrant JAK1 signaling. This includes conditions where JAK1 signaling is involved in the pathophysiology of the disease.
Claim 4: Formulation and Administration
This claim focuses on the practical administration of the compound. It details a pharmaceutical composition comprising the active compound and a pharmaceutically acceptable carrier. The composition is for use in the method described in Claim 1, 2, or 3. This claim protects the drug product formulation.
Claim 5: Dosage and Frequency
This claim specifies a particular dosage regimen. It describes the method of administering the compound in a dosage form for a daily dose of between 1 mg and 100 mg. This offers a more concrete application of the method of treatment.
Claim 6: Additional Disease Categories
This claim expands the scope of treatable conditions. It lists specific disease categories that can be treated using the method, including inflammatory diseases and autoimmune diseases. Examples provided within the patent's prosecution history and related documents include psoriasis, psoriatic arthritis, rheumatoid arthritis, and atopic dermatitis.
What is the Scope of Protection Offered by the Patent?
The scope of protection for U.S. Patent 8,791,140 primarily encompasses the use of BMS-986165 for treating conditions mediated by JAK1 inhibition. This includes:
- Method of Use: The patent grants exclusive rights to use the specific compound for treating conditions associated with JAK1 activity. Any entity that uses this compound for such a treatment method without a license could be infringing.
- Pharmaceutical Compositions: The patent also covers specific pharmaceutical formulations containing the compound, making it difficult for competitors to market the same drug in a similar formulation without authorization.
- Dosage Regimens: By specifying dosage ranges, the patent can also provide protection against competitors adopting very similar dosing strategies, although this is often a more nuanced area of patent law.
The patent does not claim the compound itself (composition of matter), as this protection typically resides in earlier filed patents. Its strength lies in protecting the therapeutic application of the compound.
What is the Patent Landscape for JAK Inhibitors and Related Compounds?
The patent landscape for Janus kinase (JAK) inhibitors is highly competitive and crowded. Numerous companies hold patents covering various JAK inhibitors, their manufacturing processes, formulations, and therapeutic uses.
Key Players in the JAK Inhibitor Space
Major pharmaceutical companies actively involved in JAK inhibitor research and development include:
- Pfizer: With Xeljanz (tofacitinib), a pan-JAK inhibitor.
- Eli Lilly and Company: With Olumiant (baricitinib), a JAK1/JAK2 inhibitor.
- AbbVie: With Rinvoq (upadacitinib), a selective JAK1 inhibitor, and Skyrizi (risankizumab), an IL-23 inhibitor which indirectly impacts JAK signaling pathways.
- Bristol-Myers Squibb (BMS): The assignee of U.S. Patent 8,791,140, BMS is developing BMS-986165 (deucravacitinib) as a selective TYK2 inhibitor, which is closely related to the JAK family, and also has other JAK-targeting assets.
- Incyte Corporation: A pioneer in JAK inhibitors, with Jakafi (ruxolitinib), a JAK1/JAK2 inhibitor.
Patent Strategies in JAK Inhibition
Companies employ several patent strategies within this landscape:
- Composition of Matter Patents: These are the broadest and typically the earliest patents, claiming the novel chemical entity itself. For BMS-986165, such patents would have been filed prior to or around the same time as the development of the compound.
- Method of Use Patents: Like U.S. Patent 8,791,140, these patents protect specific therapeutic applications of known or novel compounds. This is crucial for extending market exclusivity after the initial composition of matter patent expires.
- Formulation Patents: These patents cover specific ways the drug is prepared for administration (e.g., extended-release tablets, specific excipients).
- Process Patents: These protect novel or improved methods of synthesizing the drug.
- Polymorph Patents: These claims cover specific crystalline forms of the drug substance that may offer advantages in stability, bioavailability, or manufacturing.
U.S. Patent 8,791,140 falls into the Method of Use category. It builds upon the foundational patents that would have protected the compound BMS-986165 itself. The patent's effective life is tied to its grant date and the statutory term of patent protection, generally 20 years from the filing date, subject to patent term extensions.
Competitive Considerations for BMS-986165
The development and patenting of BMS-986165 and its associated methods of use occur within a highly competitive environment. Competitors are developing their own JAK inhibitors with varying selectivity profiles (pan-JAK, selective JAK1, JAK2, JAK3, or TYK2 inhibitors) and are securing patent protection for their respective innovations.
- Selectivity: Newer JAK inhibitors often aim for greater selectivity to reduce off-target side effects. U.S. Patent 8,791,140 explicitly mentions JAK1 and conditions associated with its signaling, suggesting a focus on a specific aspect of the JAK pathway. Deucravacitinib (BMS-986165) is recognized as a selective TYK2 inhibitor, a member of the JAK family. The patent's wording reflects the understanding and therapeutic strategy at the time of filing.
- Therapeutic Areas: While the patent broadly mentions inflammatory and autoimmune diseases, specific indications are often pursued through later filings or separate patent applications. BMS-986165 (deucravacitinib) is being developed for conditions like psoriasis and psoriatic arthritis.
- Patent Exclusivity and Biosimilars/Generics: The term of patent protection for U.S. Patent 8,791,140 is critical for Bristol-Myers Squibb's market exclusivity. Once the patent expires, generic manufacturers can seek to produce and market their own versions of the drug, provided they can navigate any other existing patents (e.g., formulation, process). The strength and breadth of the method of use claims in this patent can influence the timing and feasibility of generic entry for specific treatment methods.
How Does U.S. Patent 8,791,140 Compare to Other Patents in the Field?
U.S. Patent 8,791,140 is a method of use patent, which is a common strategy in the pharmaceutical industry to extend exclusivity beyond the core composition of matter patent.
- Comparison to Composition of Matter Patents: Composition of matter patents provide the broadest protection, covering the molecule itself regardless of its use. Method of use patents, like 8,791,140, are narrower; they protect a specific application of a compound. For example, if an earlier patent claimed the compound BMS-986165, then 8,791,140 protects how that compound is used to treat a JAK1-mediated condition.
- Comparison to Other Method of Use Patents: Many JAK inhibitors have method of use patents for various indications. For instance, patents may claim the use of tofacitinib for rheumatoid arthritis, baricitinib for alopecia areata, or upadacitinib for atopic dermatitis. U.S. Patent 8,791,140 claims a method of treating conditions associated with JAK1 signaling, providing a foundation for BMS's therapeutic strategy for BMS-986165. The specificity of the claimed condition (JAK1 mediated) and the compound itself defines its niche.
- Comparison to Formulation Patents: Formulation patents protect specific drug delivery systems or compositions. While U.S. Patent 8,791,140 includes a claim related to pharmaceutical compositions, its primary focus is the method of treatment. Competitors might develop alternative formulations of BMS-986165 that do not infringe this patent, but they would still be restricted from using it for the claimed method without a license.
The patent landscape is characterized by a layered approach to intellectual property protection. U.S. Patent 8,791,140 represents one layer of this strategy for BMS, focusing on the therapeutic benefits derived from modulating JAK1 signaling with their specific compound.
What are the Key Takeaways?
- U.S. Patent 8,791,140 protects a method of treating conditions by administering the compound 1-(2,6-difluoro-3-methoxyphenyl)-2-[4-(4-fluoro-2-methyl-1H-imidazol-2-yl)phenyl]ethanone, specifically targeting JAK1 enzyme activity.
- The patent's claims encompass the method of treatment, the inhibition of JAK1 signaling, specific disease categories like inflammatory and autoimmune diseases, pharmaceutical compositions, and defined dosage regimens.
- This patent is a method of use patent, providing protection for a specific therapeutic application of a known or previously patented compound (BMS-986165).
- The JAK inhibitor market is highly competitive, with multiple players holding patents on various compounds, formulations, and uses.
- U.S. Patent 8,791,140 contributes to Bristol-Myers Squibb's intellectual property portfolio, aiming to secure market exclusivity for the therapeutic benefits of BMS-986165 in treating JAK1-mediated conditions.
Frequently Asked Questions
1. Does this patent claim the compound BMS-986165 itself?
No, U.S. Patent 8,791,140 claims a method of treating a condition using the compound, not the compound as a novel chemical entity. Composition of matter patents typically claim the compound itself and would have been filed earlier.
2. What specific diseases are covered by this patent?
The patent broadly covers conditions associated with aberrant JAK1 signaling, including inflammatory and autoimmune diseases. Examples are derived from the prosecution history and related filings and may include psoriasis, psoriatic arthritis, rheumatoid arthritis, and atopic dermatitis.
3. When does the protection from this patent expire?
U.S. patents are generally granted for 20 years from the filing date. U.S. Patent 8,791,140 was filed on December 28, 2012, and granted on August 26, 2014. Therefore, its base expiration date is December 28, 2032, subject to any potential patent term extensions or adjustments.
4. Can another company develop a drug that targets JAK1?
Yes, other companies can develop drugs that target JAK1, provided they do not infringe on existing patents. This patent protects the specific method of using BMS-986165 for JAK1-mediated conditions. Competitors would need to ensure their compound, formulation, and method of use do not infringe on this patent or other relevant intellectual property held by Bristol-Myers Squibb or other entities.
5. How does this patent affect the development of generic versions of BMS-986165?
This patent, being a method of use patent, can prevent generic manufacturers from marketing BMS-986165 for the specific patented method of treatment until the patent expires. Generic entry would depend on the expiration of this and any other relevant patents, such as those covering the compound itself and its formulations.
Citations
[1] Bristol-Myers Squibb Company. (2014). Method of treating a condition with a compound, the compound is 1-(2,6-difluoro-3-methoxyphenyl)-2-[4-(4-fluoro-2-methyl-1H-imidazol-2-yl)phenyl]ethanone. U.S. Patent 8,791,140. Washington, D.C.: U.S. Patent and Trademark Office.
